SLC10A2 and Cholestatic liver disease: The use of IBAT inhibitors for the treatment of pediatric cholestatic liver disease has been reviewed recently.5 Whereas a variety of genetic, immune, and environmental factors initiate cholestatic liver disease,31,32,121 retained BAs have been implicated as a common contributor to disease pathogenesis and progression.1,2,3,4 Based on their ability to redirect the BA circulation, gut-restricted IBAT inhibitors have been postulated to act in part by decreasing hepatic BA accumulation.122–124 It should be noted that this mechanism is not unique to IBAT inhibitors.